Dosimetric and clinical outcomes with intensity-modulated radiation therapy for middle-aged and elderly patients with stage Ⅲ esophageal squamous cell cancer
10.3760/cma.j.issn.0254-9026.2017.10.012
- VernacularTitle:中老年Ⅲ期食管鳞癌患者根治性调强放疗的预后和剂量研究
- Author:
Yonggang XU
1
;
Dazhi CHEN
;
Chunlin LIU
;
Qinhong WU
;
Hong GAO
;
Qiuzi ZHONG
;
Xia XIU
;
Gaofeng LI
Author Information
1. 100730,北京医院国家老年医学中心放疗科
- Keywords:
Esophageal neoplasms;
Radiotherapy;
Prognosis
- From:
Chinese Journal of Geriatrics
2017;36(10):1107-1111
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the dosimetric benefit,prognosis and toxicity of intensitymodulated radiation therapy (IMRT) for stage Ⅲ esophageal squamous cell cancer.Methods This was a retrospective analysis of 28 patients,aged between 45 and 83 years,with stage Ⅲ esophageal squamous cell cancer who had received radical IMRT.Of these patients,six received concurrent chemotherapy and eight received targeted therapy.The median radiotherapy dose was 67.1 Gy.Dosimetric parameters for the target volume and critical normal structures were evaluated by dose volume histogram.The Kaplan-Meier method was used to calculate overall survival (OS),progress free survival (PFS) and locoregional control (LRC).Results The mean conformity index (CI) and homogeneity index (HI) scores of the planning target volume (PTV) were 0.82 and 0.92,respectively,indicating very good coverage of the target volume.Three-year OS,PFS,and LRC were 48.0 ％,31.2％,and 62.0％,respectively.Acute toxicities were mild,only two patients developed acute esophagitis (grade ≥3),and three had acute pneumonitis (grade ≥2).Conclusions IMRT can provide excellent dose conformity and achieve favorable LRC and survival with only mild toxicities in patients with stage Ⅲ esophageal squamous cancer.
